Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Onalespib in Advanced Solid Tumors and Recurrent TNBC/Ovarian Cancer
NCT02898207Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of onalespib and olaparib in malignant solid neoplasm, ovarian carcinoma, fallopian tube carcinoma (PFTC) and 2 more, sponsored by National Cancer Institute. Started May 2017; status: completed.
02
Drugs
onalespibolaparib
03
Conditions
malignant solid neoplasmovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)breast carcinoma
Beyond the preview
Go deeper on NCT02898207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02898207.